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Incidence and Management of
Restenosis After Treatment of Unprotected
Left Main Disease With Drug-Eluting Stents
70 Restenotic Cases From a Cohort of 718 Patients:
FAILS (Failure in Left Main Study)
Imad Sheiban, MD,* Dario Sillano, MD,* Giuseppe Biondi-Zoccai, MD,* Alaide Chieffo, MD,†
Antonio Colombo, MD,† Sabine Vecchio, MD,‡ Massimo Margheri, MD,‡ Julian P. Gunn, MD,§
Tushar Raina, MD,§ Francesco Liistro, MD, Leonardo Bolognese, MD, Michael S. Lee, MD,¶
Jonathan Tobis, MD,¶ Claudio Moretti, MD, PHD*
Turin, Milan, Ravenna, and Arezzo, Italy; Sheffield, United Kingdom; and Los Angeles, California
Objectives This study sought to retrospectively appraise the incidence and management of restenosis after drug-eluting
stent (DES) implantation for unprotected left main (ULM) disease.
Background The promising role of DES for ULM has been reported. However, no detailed data are available on subsequent
restenosis.
Methods From the total sample of patients with ULM treated with DES, we identified those presenting with angiographic
ULM restenosis. The primary end point was the long-term rate of major adverse cardiac events (MACE), that is,
death, myocardial infarction (MI), or target lesion revascularization (TLR). We also adjudicated stent thrombosis
according to the Academic Research Consortium.
Results Post-DES restenosis in ULM occurred in 70 of 718 patients (9.7%). Of these, 59 (84.3%) were treated percutane-
ously (34 [48.6%] with additional DES, 22 [31.4%] with standard or cutting balloons, 2 [2.9%] with rotational
atherectomy, and 1 [1.4%] with a bare-metal stent), whereas 7 (10%) patients underwent bypass surgery and 4
(5.7%) were treated medically. In-hospital MACE included no periprocedural MI and only 1 (1.4%) death. After
27.2  15.4 months, MACE occurred cumulatively in 18 (25.7%) patients, with death in 4 (5.7%), MI in 2
(2.9%), and TLR in 15 (21.4%). Patients treated with medical, interventional, and surgical therapy had the fol-
lowing MACE rates, respectively: 50%, 25.4%, and 14.3%. Definite, probable, and possible stent thrombosis oc-
curred in 0 (0%), 1 (1.4%), and 1 (1.4%) patient, respectively.
Conclusions DES restenosis in the ULM artery can be managed in most cases with a minimally invasive approach, achieving
favorable early and late results. (J Am Coll Cardiol 2009;54:1131–6) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.06.018t
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Uignificant unprotected left main disease (ULM) occurs in 5%
o 10% of patients undergoing coronary angiography, and since
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Manuscript received February 2, 2009; revised manuscript received June 1, 2009,
ccepted June 1, 2009.he 1970s, coronary artery bypass grafting (CABG) has been
onsidered its preferred treatment (1). Balloon-only percuta-
eous coronary intervention (PCI) for ULM is complicated by
arly elastic recoil, abrupt closure, and late restenosis. Bare-
etal stents have improved immediate results, but restenosis
ith ensuing repeat target lesion revascularization (TLR) or
udden death remain major limitations (2).
Drug-eluting stents (DES) significantly reduce the risk of
estenosis, and in some institutions, it has become common
ractice to perform PCI with DES for ULM (3,4). Despite
he relatively common occurrence of DES restenosis in
LM (reaching 10% to 20%), there are no data on the
ptimal management of such patients. The purpose of this
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Restenosis After ULM Stenting September 22, 2009:1131–6multicenter, international, retro-
spective study was to assess the
outcome of patients with ULM
restenosis after PCI with DES.
Methods
Study design and patient popu-
lation. All consecutive patients
with an angiographic diagnosis
of significant restenosis (50%
diameter stenosis at coronary an-
giography) in the ULM were
retrospectively selected after PCI
with DES of the ULM (July
2002 to October 2006). All pa-
tients were included in the study
independent of the subsequent
decision for medical, interven-
ional, or surgical treatment. At least 6 months of clinical
ollow-up beyond the documentation of ULM restenosis
as required for inclusion. Subjects with protected left main
essels, defined as the presence of at least 1 patent arterial or
enous graft to the left coronary artery, were excluded.
ritten informed consent was obtained by all patients,
nd ethical committee approval was obtained for database
eview.
Figure 1 Study Profile
angio  angiographic; CABG  coronary artery bypass grafting; DES  drug-eluting
Abbreviations
and Acronyms
CABG  coronary artery
bypass grafting
CK  creatine kinase
DES  drug-eluting stent(s)
MACE  major adverse
cardiovascular events
MI  myocardial infarction
PCI  percutaneous
coronary intervention
ST  stent thrombosis
TLR  target lesion
revascularization
ULM  unprotected left
main diseasenterventional procedures and post-intervention medica-
ions. Coronary angioplasty and stent implantation during
ndex PCI were performed according to current practice and
uidelines. The choice of devices, techniques (including the
pproach to bifurcation stenting, kissing balloon, and post-
ilatation), and drug therapy (including glycoprotein IIb/
IIa inhibitors) for the index procedure was at the cardiol-
gist’s choice. After the procedure, all patients were advised to
ontinue lifelong aspirin and either 250-mg ticlopidine twice
aily or 75-mg clopidogrel for 6 to 12 months or more. The
hoice between angiographic and clinical follow-up was at the
perator’s and referring physician’s discretion, but often took
nto account the patient’s preference and comorbidities. None-
heless, in most cases angiographic follow-up was recom-
ended irrespective of symptoms or signs of ischemia 6 to 12
onths after the index PCI. Treatment of restenosis was also
ompletely at the cardiologist’s discretion, but usually each case
as collectively discussed and the final management decision
as based on the patient’s symptoms/signs of ischemia, coro-
ary anatomy, surgical risk, PCI feasibility, and overall life
xpectancy. In case of repeat PCI, the choice of technique and
evice was also at the interventionist’s discretion.
nd point definitions and follow-up. The primary end
oint of the study was the occurrence of major adverse
ardiovascular events (MACE), that is, death, myocardial
nfarction (MI), or TLR (defined as repeat PCI or CABG
(s); PCI  percutaneous coronary intervention; ULM  unprotected left main.stent
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September 22, 2009:1131–6 Restenosis After ULM Stentingor significant restenosis in the previously stented segment
r in the adjacent 5 mm). Diagnosis of MI at follow-up was
ased on peak of total creatine kinase (CK) 2 times the
Baseline CharacteristicsTable 1 Baseline Characteristics
All
(n  70)
Age, yrs 65.4 12.8
Men 59 (84.3)
Diabetes mellitus 18 (26.1)
Noninsulin-dependent 12 (66.7)
Insulin-dependent 6 (33.3)
Hypertension 50 (72.5)
Dyslipidemia 49 (70.9)
Current smoking 5 (7.4)
Left ventricular ejection fraction, % 52.4 9.4
Prior myocardial infarction 20 (43.5)
Prior CABG 6 (13.0)
Clinical presentation of restenosis
Elective control 15 (22.1)
Silent myocardial ischemia 12 (17.6)
Stable angina 20 (29.4)
Unstable angina 19 (27.9)
Acute myocardial infarction 2 (2.9)
Cardiogenic shock 1 (1.5)
EuroSCORE 6.9 11.7
Values are mean  SD or n (%).
CABG  coronary artery bypass grafting; PCI  percutaneous coron
Angiographic and Procedural Characteristics ofProcedure in the ULM, Before t e Diagnosis of RTable 2 Angiog aphic and Procedu al CharaProcedure in the ULM, Before the D
All
(n  70)
Lesion location
Ostium only 12 (17.1)
Ostium and/or shaft 9 (12.9)
Distal and/or bifurcational 49 (70.0)
PCI in the ULM
Atherectomy 2 (3.6)
No. of implanted stents 1.7 0.8
Only SES 38 (55.9)
Only PES 25 (36.8)
Only ZES 2 (2.9)
SES and PES 1 (1.5)
DES and BMS 2 (2.9)
Total stent length per patient, mm 26.7 13.6
Maximum balloon diameter, mm 3.33 0.56
Maximum dilation pressure, atm 15.9 3.8
Bifurcation stenting 52 (74.3)
Main branch only 14 (26.9)
T 9 (17.3)
V 5 (9.6)
Crushing 11 (21.2)
Culottes 2 (3.8)
Simultaneous kissing stenting 10 (19.2)
Final kissing balloon inflation 47 (90.4)
Values are mean  SD or n (%). *Defined as ULM and/or ostial left a
BMS  bare-metal stent(s); PCI  percutaneous coronary intervention; PES
unprotected left main; ZES  zotarolimus-eluting stent(s).pper limit for normal and a concomitant increase of
K-MB over the upper limit of normal and/or ratio of peak
K-MB/peak total CK 0.10 and/or CK-MB 3 times
dical Therapy Only
(n  4)
Repeat PCI
(n  59)
CABG
(n  7)
67.6 21.2 64.8 12.7 69.7 8.9
3 (75.0) 49 (83.1) 7 (100)
0 18 (31.0) 0
0 12 (20.7) 0
0 6 (10.3) 0
3 (75.0) 43 (74.1) 4 (57.1)
3 (75.0) 41 (69.5) 5 (71.4)
0 3 (5.3) 2 (28.6)
43.0 23.4 53.9 9.5 45.0 7.1
2 (50.0) 18 (45.0) 0
0 6 (15.0) 0
1 (25.0) 13 (22.8) 1 (14.3)
0 11 (19.3) 1 (14.3)
1 (25.0) 16 (28.1) 3 (42.9)
2 (50.0) 15 (26.3) 2 (28.6)
0 2 (3.5) 0
0 1 (1.8) 0
7.0 6.1 7.1 13 5.0 1.9
rvention.
irstnosis*tic of the First
osis of Restenosis*
dical Therapy Only
(n  4)
Repeat PCI
(n  59)
CABG
(n  7)
1 (25.0) 9 (15.3) 2 (28.6)
0 8 (13.6) 1 (14.3)
3 (75.0) 42 (71.2) 4 (57.1)
0 2 (4.2) 0
2.0 0.8 1.7 0.9 1.4 0.8
3 (75.0) 33 (57.9) 2 (28.6)
1 (25.0) 20 (35.1) 4 (57.1)
0 1 (1.8) 1 (14.3)
0 1 (1.8) 0
0 2 (3.5) 0
36.0 21.4 26.5 13.3 23.0 11.3
2.94 0.13 3.40 0.55 2.96 0.59
15.0 4.2 16.1 3.9 14.4 2.2
3 (75.0) 45 (76.3) 4 (57.1)
0 13 (28.9) 1 (25.0)
0 9 (20.0) 0
0 4 (8.9) 1 (25.0)
0 10 (22.2) 1 (25.0)
0 2 (4.4) 0
3 (100) 6 (13.3) 1 (25.0)
2 (75.0) 41 (91.1) 4 (100)
descending and/or ostial left circumflex and/or ostial ramus.Methe Festect ris
iagn
Me
nterior
 paclitaxel-eluting stent(s); SES  sirolimus-eluting stent(s); ULM 
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Restenosis After ULM Stenting September 22, 2009:1131–6he upper limit of normal. Stent thrombosis (ST) was
djudicated according to the Academic Research Consor-
ium (5). Data were obtained by direct visits, telephone
nterviews, and queries of institutional electronic databases,
eferring physicians, or municipal civil registries.
tatistical analysis. Continuous variables are expressed as
ean  SD and were compared by analysis of variance or
osset t test. Categorical variables are presented as counts
nd percentages, and were compared by chi-square test. The
values unadjusted for multiplicity are reported throughout,
ith statistical significance set at the 2-tailed 0.05 level.
tatistical analyses were performed with SPSS version 12.0
SPSS, Inc., Chicago, Illinois).
esults
aseline clinical characteristics. From a total of 718
atients, with follow-up status available in 97.5%, 5.1% died
2.5% suddenly) before 6 months without any angiographic
ollow-up (Fig. 1). Angiographic follow-up was ultimately
erformed in 62.8% of subjects, being clinically driven in
6.6% and routinely performed even in the absence of
Angiographic and Procedural Characteristicsof the Procedure Sh wing the ULM R stenosis*Table 3 Angiog aphic and Procedu al Charaof the Procedure Showing the ULM
Lesion characteristics
Ostium only
Ostium and/or shaft
Distal and/or bifurcational
Restenosis involving ostial left anterior descending
Restenosis involving ostial left circumflex
Restenosis involving ramus
Diffuse restenosis
PCI for ULM restenosis
Balloon-only PCI
Cutting balloon
Directional atherectomy
PCI with BMS
PCI with DES
Number of implanted stents
Only SES
Only PES
Maximum balloon diameter, mm
Total stent length per patient, mm
Maximum dilation pressure, atm
Bifurcation stenting
Main branch only
T
V
Crushing
Culottes
Simultaneous kissing stenting
Final kissing balloon inflation
Glycoprotein IIb/IIIa inhibitors
Intra-aortic balloon pumpValues are mean  SD or n (%). *Defined as ULM and/or ostial left anterior
Abbreviations as in Table 2.ymptoms/signs of myocardial ischemia in 46.2%. Patients
ndergoing routine angiographic follow-up were signifi-
antly younger (74.5  11.0 years vs. 64.0  9.1 years, p 
.001 at Gosset t test) and had a lower European System for
ardiac Operative Risk Evaluation (EuroSCORE) (5.4 
.9 vs. 2.2  0.7, p  0.001 at Gosset t test) than those not
erforming such follow-up.
Restenosis in the ULM after PCI with DES occurred in
0 of 718 patients (9.7%). Of these, 5.7% were treated with
edical therapy only, 84.3% by repeat PCI, and 10%
nderwent CABG (Table 1). The repeat PCI group was
haracterized by a trend toward a higher prevalence of
iabetes (0% vs. 31% vs. 0%, p 0.10 at chi-square test) but
lso by higher ejection fraction (43.0  23.4 vs. 53.9  9.5
s. 45.0  7.1, p  0.02 at analysis of variance). Globally,
2.1% of restenoses were diagnosed during routine follow-up
ngiogram and 30.8% had an admission diagnosis of acute
oronary syndrome.
ngiographic and procedural characteristics. Angio-
raphic and procedural characteristics of the first procedure
n the ULM (before the diagnosis of restenosis) are reported
tics
enosis*
0)
Medical Therapy Only
(n  4)
Repeat PCI
(n  59)
CABG
(n  7)
.9) 1 (25.0) 10 (16.9) 1 (14.3)
.0) 0 12 (20.3) 2 (28.6)
.9) 3 (75.0) 37 (62.7) 4 (57.1)
.8) 0 19 (51.4) 3 (50.0)
.1) 3 (100) 30 (81.1) 2 (33.3)
.0) 0 4 (10.8) 2 (33.3)
.1) 0 10 (16.9) 2 (28.6)
— 16 (27.1) —
— 6 (10.2) —
— 2 (3.4) —
— 1 (1.7) —
— 34 (57.6) —
— 1.3 0.5 —
— 13 (39.4) —
— 20 (60.6) —
— 3.3 0.4 —
— 17.7 10.4 —
— 17.7 5.0 —
— 27 (45.8) —
— 15 (62.5) —
— 2 (8.3) —
— 3 (12.5) —
— 0 —
— 1 (4.2) —
— 3 (12.5) —
— 21 (87.5) —
— 9 (13.8) —
— 5 (7.2) —cteris
Rest
All
(n  7
12 (16
14 (20
44 (62
22 (47
35 (76
6 (13
12 (17
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—
—descending and/or ostial left circumflex and/or ostial ramus.
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September 22, 2009:1131–6 Restenosis After ULM Stentingn Table 2, whereas angiographic and procedural character-
stics of the procedure showing the ULM restenosis, that is,
he index procedure for the purpose of this work, are
eported in Table 3. The location of restenosis was not
ignificantly associated with the subsequent management
trategy, even if PCI was the most common approach in all
ases. Specifically, distal ULM disease was managed by PCI
n 84.1%, by CABG in 9.1%, and by medical therapy in
.8%, whereas ostial or shaft disease was managed by PCI in
4.6%, by CABG in 3.9%, and by medical therapy in 11.5%
p  0.839 at chi-square test comparing distal versus
ondistal location). Among the 59 patients treated inter-
entionally (repeat PCI group), 57.6% underwent a new
ES implantation. In contrast to the previous baseline
rocedure, paclitaxel-eluting stents were used predomi-
antly (60.6%), followed by sirolimus-eluting stents
39.4%). Among the 70 restenotic patients, CABG was
erformed only for in-stent restenosis with no case of
ABG for disease progression elsewhere.
n-hospital and long-term outcomes. The immediate
utcome was quite favorable (Table 4), with 1 (1.7%) death
n the PCI group. No patient had periprocedural MI or
eeded urgent CABG. Long-term follow-up data were
vailable in 100% of restenotic subjects after an average of
5.6  16.5 months since diagnosis of restenosis (36.7 
5.3 months of follow-up from the first PCI with DES in
he ULM), with 44.3% of subjects undergoing repeat PCI
aving repeat angiographic follow-up after 8.1  8.3
onths. The MACE rate was 25.7%, with death in 5.7%,
I in 2.9%, TLR in 21.4% (including CABG in 5.7%), and
CI on other vessels in 21.4%. Finally, 1 case of possible
In-Hospital and Long-Term Follow-Up EventsTable 4 In-Hospital and Long-Term Follow-Up
All
(n  70)
In-hospital events
Death 1 (1.4)
Cardiac death 1 (1.4)
Myocardial infarction 0
CABG 0
Long-term events
Follow-up completed 70 (100)
Follow-up from restenosis, months 25.6 16
Follow-up from first PCI in ULM, months* 36.7 15
MACE 18 (25.7)
Death 4 (5.7)
Cardiac death 2 (2.9)
Myocardial infarction 2 (2.9)
CABG 4 (5.7)
ULM TLR 15 (21.4)
Non-ULM* PCI 15 (21.4)
Stent thrombosis
Definite 0
Probable 1 (1.4)
Possible 1 (1.4)Values aremean SD or n (%). *Defined as ULM and/or ostial left anterior desce
Abbreviations as in Table 2.T, 1 case of probable ST, and no cases of definite ST were
dentified (all in the PCI group).
iscussion
rug-eluting stenting in the ULM has become a common
ractice in several tertiary care centers. Despite encouraging
esults, restenosis is still a challenging issue, especially in
uch a delicate anatomic position. In the scientifically
igorous and randomized SYNTAX (SYNergy Between
CI With TAXUS and Cardiac Surgery) trial, 12-month
ACE rates reached 17.8% in the PCI group and 12.1% in
he CABG group, with repeat revascularization rates of
3.7% and 5.9% (4). Seung et al. (6) compared in a
onrandomized fashion PCI versus CABG, showing after
3 months that they did not differ significantly for death
ates or the composite of death, MI, or stroke. However,
ES were associated with higher rates of TLR (9.7% vs.
.6%). Similar results were also reported by other investi-
ators (3).
Despite the increasing frequency of ULM restenotic cases
n clinical practice (as it occurs in up to 16.7% of subjects
reated with DES in the ULM) (7) and its important
linical impact, ULM restenosis after PCI with DES has
een incompletely characterized. The present retrospective
onrandomized study is the first to evaluate the outcome of
uch patients. Our major findings evaluating 70 restenotic
ases of 718 initial ULM patients are 2-fold: 1) significant
LM DES restenosis is often characterized by a stable clinical
ondition; and 2) after 24 months of clinical follow-up from
nts
Medical Therapy Only
(n  4)
Repeat PCI
(n  59)
CABG
(n  7)
0 1 (1.7) 0
0 1 (1.7) 0
0 0 0
0 0 0
4 (100) 59 (100) 7 (100)
27.1 18.5 23.9 16.8 32.4 9.2
45.1 17.4 35.5 15.7 44.3 10.8
2 (50.0) 15 (25.4) 1 (14.3)
1 (25.0) 3 (5.1) 0
1 (25.0) 1 (1.7) 0
0 2 (3.4) 0
0 3 (5.1) 1 (14.3)
1 (25.0) 13 (22.0) 1 (14.3)
1 (25.0) 14 (23.7) 0
0 0 0
0 1 (1.7) 0
0 1 (1.7) 0Eve
.5
.3nding and/or ostial left circumflex and/or ostial ramus revascularization.
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Restenosis After ULM Stenting September 22, 2009:1131–6he diagnosis of restenosis, MACE rates seem quite favorable
n both the interventional and surgical therapy groups.
Almost 70% of patients with a diagnosis of significant
ES restenosis in ULM were elective angiographic control
ubjects or presented with silent ischemia or stable angina,
ut an unstable presentation of ULM restenosis in over 30%
f cases suggests that restenosis is not a benign entity even
n the ULM. Nonetheless, repeat PCI is often possible and
uccessful in these subjects. Notably, paclitaxel-eluting
tents were used more frequently for repeat PCI, possibly
ecause of availability subsequent to sirolimus-eluting
tents, larger sizes, and preference for different DES strategy
8). Regarding the midterm clinical outcome (more than 2
ears of median follow-up after the diagnosis of restenosis),
his study showed low mortality and MI rates in patients
reated by PCI and CABG. Differences in MACE, death,
I, and TLR rates between these 2 groups are, however,
imited by the small size of the CABG group, and should be
iewed as hypothesis-generating only. It should also be
orne in mind that follow-up intervention results are largely
ependent on the initial patient characteristics and inter-
entional approach, as, for instance, in our study multiple
tents were commonly implanted, limiting the role of
ubsequent CABG. These findings can also be compared
ith those reported on DES restenosis in other coronary
ocations. Specifically, Mishkel et al. (9) reported 12-month
ates of death, MI, and TLR of 8.7%, 2.2%, and 30.6%,
espectively, in unselected DES restenotic cases.
tudy limitations. This study has several critical limita-
ions, including the retrospective nonrandomized design
nd the descriptive scope, which leaves ample room for bias
n patient and management strategy selection. Thus, com-
arative data between treatments are hypothesis-generating
nly. In addition, no blinded adjudication committee was
et up, but the risk of data acquisition and adjudication bias
as kept to a minimum by relying on hard clinical end
oints and established definitions. Lack of national regis-
ries may lead to underestimations of long-term event rates.
owever, losses to follow-up were overall lower than 3.0%,
hus largely limiting the risk of underestimating the primary
nd point. Most of the patients had good cardiac systolic
unction; thus, our findings cannot be directly applied to
atients with left ventricular systolic dysfunction. Finally,
he study size seems relatively small, especially in compari-
on with studies on non-ULM restenosis, and as also
estified by the large 95% confidence intervals for the
K
crimary end point (16.9% to 37.0% for the total population,
5.0% to 85.0% for medical therapy, 16.1% to 37.8% for
epeat PCI, and 2.6% to 51.3% for CABG). However,
estenosis in the ULM remains uncommon, and only a
tudy pooling several dozen tertiary care centers could
rovide much larger data than our study.
onclusions
his multicenter, international registry suggests that PCI
an be a safe and effective treatment of ULM restenosis after
ES implantation.
eprint requests and correspondence: Dr. Giuseppe Biondi-
occai, Interventional Cardiology, Division of Cardiology, Uni-
ersity of Turin, S. Giovanni Battista Molinette Hospital, Corso
ramante 88-90, 10126 Turin, Italy. E-mail: gbiondizoccai@
mail.com.
EFERENCES
. Sheiban I, Sillano D, Biondi-Zoccai GG, et al. Current management of
unprotected left main coronary artery disease: run-in survey of the
RITMO (Registro Italiano sul Trattamento del tronco coMune non
protettO) study. Available at: http://dx.doi.org/10.1016/j.ijcard.2008.
05.009. Accessed August 4, 2009.
. Takagi T, Stankovic G, Finci L, et al. Results and long-term predictors
of adverse clinical events after elective percutaneous interventions on
unprotected left main coronary artery. Circulation 2002;106:698–702.
. Biondi-Zoccai GG, Lotrionte M, Moretti C, et al. A collaborative
systematic review and meta-analysis on 1278 patients undergoing
percutaneous drug-eluting stenting for unprotected left main coronary
artery disease. Am Heart J 2008;155:274–83.
. Serruys PW, Morice MC, Kappetein AP, et al., for the SYNTAX
Investigators. Percutaneous coronary intervention versus coronary-
artery bypass grafting for severe coronary artery disease. N Engl J Med
2009;360:961–72.
. Cutlip DE, Windecker S, Mehran R, et al., for the Academic Research
Consortium. Clinical end points in coronary stent trials: a case for
standardized definitions. Circulation 2007;115:2344–51.
. Seung KB, Park DW, Kim YH, et al. Stents versus coronary-artery
bypass grafting for left main coronary artery disease. N Engl J Med
2008;358:1781–92.
. Price MJ, Cristea E, Sawhney N, et al. Serial angiographic follow-up of
sirolimus-eluting stents for unprotected left main coronary artery
revascularization. J Am Coll Cardiol 2006;47:871–7.
. Cosgrave J, Melzi G, Corbett S, et al. Repeated drug-eluting stent
implantation for drug-eluting stent restenosis: the same or a different
stent. Am Heart J 2007;153:354–9.
. Mishkel GJ, Moore AL, Markwell S, Shelton MC, Shelton ME.
Long-term outcomes after management of restenosis or thrombosis of
drug-eluting stents. J Am Coll Cardiol 2007;49:181–4.ey Words: coronary artery disease y drug-eluting stent y left main
oronary artery y percutaneous coronary intervention y restenosis.
